A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Overview

The trial's objective is to evaluate the immunogenicity of repeated single doses of dasiglucagon* and GlucaGen following subcutaneous (SC) administration in patients with type 1 diabetes mellitus (T1DM) and further to evaluate the safety and tolerability of dasiglucagon and GlucaGen. *dasiglucagon is the proposed International Nonproprietary Name (pINN) for ZP4207

Full Title of Study: “A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen® Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: February 13, 2018

Detailed Description

Patients with T1DM were randomly assigned in a 1:1 ratio to receive 3 SC injections of either dasiglucagon (0.6 mg) or GlucaGen (1 mg), with 1 week between doses. Patients were followed for 15 weeks from the day of the first dose to assess the immune response. Patients with previous exogenic glucagon exposure were not excluded from the trial, but the information on previous glucagon administration was recorded to enable subgroup analyses. It was expected that 112 patients in total would be randomly assigned to treatment groups and treated. A total of 90 patients were expected to complete the trial (45 in each treatment arm). To qualify as completed, the patient had to be dosed according to the procedure described in the protocol and to have blood drawn for the antidrug antibody analyses as scheduled.

Interventions

  • Drug: dasiglucagon
    • Glucagon Analog
  • Drug: GlucaGen
    • Native Glucagon

Arms, Groups and Cohorts

  • Experimental: dasiglucagon (ZP4207)
    • Repeated single fixed doses (s.c.injection) of dasiglucagon
  • Experimental: GlucaGen
    • Repeated single fixed doses (s.c.injection) of GlucaGen

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Patients With ADA
    • Time Frame: 104 days after the first dose
    • Percentage of the combined results of treatment-induced ADA-positive patients and treatment-boosted ADA-positive patients out of the total number of evaluable patients. ADA = antidrug antibodies.

Secondary Measures

  • Percentage of Patients With Treatment-induced ADA
    • Time Frame: 104 days after the first dose
    • Percentage of the total number of evaluable patients that were ADA negative at baseline and ADA positive after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies
  • Percentage of Patients With Treatment-boosted ADA
    • Time Frame: 104 days after the first dose
    • Percentage of baseline ADA-positive patients with significant increases (≥5-fold) in ADA titre after drug administration out of the total number of evaluable patients. ADA = antidrug antibodies
  • Characterization of ADA Response – Neutralizing Activity
    • Time Frame: 104 days after the first dose
    • Percentage of ADA positive patients with ADA neutralizing activity. ADA = antidrug antibodies.
  • Characterization of ADA Response – Titer of Neutralizing Activity
    • Time Frame: 104 days after the first dose
    • Titre of neutralizing activity of ADA positive patients. ADA = antidrug antibodies.
  • Characterization of ADA Response – Cross-reactivity
    • Time Frame: 104 days after the first dose
    • Percentage of ADA positive patients with cross-reactivity towards endogenous glucagon. ADA = antidrug antibodies.
  • Characterization of ADA Response – Timing
    • Time Frame: 104 days after the first dose
    • The timing of detected ADA response. ADA = antidrug antibodies.
  • Characterization of ADA Response – Duration
    • Time Frame: 104 days after the first dose
    • The Duration of detected ADA response. ADA = antidrug antibodies.
  • Pharmacokinetics – Area Under the Plasma Concentration Curve
    • Time Frame: 0-30 minutes
    • Area under the plasma concentration curve (AUC) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.
  • Pharmacokinetics – Area Under the Plasma Concentration Curve
    • Time Frame: 0-90 minutes
    • Area under the plasma concentration curve (AUC) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.
  • Pharmacokinetics – Maximum Plasma Concentration
    • Time Frame: 90 minutes
    • Maximum plasma concentration (Cmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.
  • Pharmacokinetics – Time to Maximum Plasma Concentration
    • Time Frame: 90 minutes
    • Time to maximum plasma concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma PK concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.
  • Pharmacodynamics – Area Under the Effect Curve
    • Time Frame: 0-30 minutes
    • Plasma glucose profiles, area under the effect curve (AUE) 0-30 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10 and 30 minutes after dosing.
  • Pharmacodynamics – Area Under the Effect Curve
    • Time Frame: 0-90 minutes
    • Plasma glucose profiles, area under the effect curve (AUE) 0-90 minutes at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.
  • Pharmacodynamics – Change From Baseline Plasma Glucose
    • Time Frame: 90 minutes
    • Change from baseline plasma glucose to maximum plasma glucose (CEmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.
  • Pharmacodynamics – Time to Maximum Plasma Glucose Concentration
    • Time Frame: 90 minutes
    • Time to maximum plasma glucose concentration (Tmax) at visit 2 and 4 (days 0 and 14). Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.
  • Pharmacodynamics – An Increase in the Plasma Glucose Concentration of ≥20 mg/dL Within 30 Minutes After Treatment
    • Time Frame: 30 minutes
    • An increase in the plasma glucose concentration of ≥20 mg/dL within 30 minutes after treatment at visit 2 and visit 4. Plasma glucose concentrations were measured before dosing and at 5, 10, 30, 60 and 90 minutes after dosing.

Participating in This Clinical Trial

Inclusion Criteria

  • Informed consent obtained before any trial-related activities (trial-related activities are any procedure that would not have been performed during normal management of the patient) – Availability for the entire trial period – Age between 18 and 70 years, both inclusive – Male or female patients with T1DM for at least 1 year. Diagnostic criteria as defined by the American Diabetes Association – Hemoglobin A1c (HbA1c) <10% – Stable anti-diabetic treatment for at least 1 month (e.g. within 10% insulin dose adjustment) Exclusion Criteria:

  • Previous administration of dasiglucagon (previously referred to as ZP4207) – Known or suspected allergy to trial medication(s) or related products – History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema) – Previous participation (randomization) in this trial – Females who are pregnant according to a positive pregnancy test, actively attempting to get pregnant, or are lactating – Patients on a closed loop artificial pancreas – Receipt of any investigational drug within 3 months prior to screening – Active malignancy within the last 5 years – Congestive heart failure, New York Heart Association class II-IV – Inadequately treated blood pressure as defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥90 mmHg at screening – Current bleeding disorder, including use of anticoagulant treatment – Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma (i.e. insulin-secreting pancreas tumor) – Known or suspected HIV infection – Use of a systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this trial – Use of systemic corticosteroids, anti-inflammatory biological agents, kinase inhibitors or other immune modulating agents within the last 3 months prior to screening – Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks prior to screening – A positive result in the alcohol and/or urine drug screen at the screening visit. Significant history of alcoholism or drug abuse as judged by the investigator or consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day for women. – Surgery or trauma with significant blood loss within the last 2 months prior to screening – Use of prescription or non-prescription medications known to cause QT prolongation

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Zealand Pharma
  • Collaborator
    • SynteractHCR
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Christina Sylvest, MSc Pharm, Study Director, Zealand Pharma A/S

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.